NCT04772534View on ClinicalTrials.gov

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

PHASE3CompletedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

April 6, 2024

Study Completion Date

April 6, 2024

Conditions
Papillomavirus Infections
Interventions
BIOLOGICAL

9vHPV vaccine

9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Trial Locations (12)

299-4503

Sotobo Children's Clinic ( Site 6616), Isumi

062-0907

Ohigesenseino Kodomo Clinic ( Site 6607), Sapporo

065-0024

Motomachi Pediatric Clinic ( Site 6606), Sapporo

593-8322

Medical Corporation Bunmeikai Okuda E.N.T ( Site 6611), Sakai

910-8561

Fukui General Hospital ( Site 6614), Fukui

542-0076

Nomura Clinic Namba ( Site 6608), Osaka

554-0014

Medical Corporation Kanyukai Kikumori Otolaryngology Clinic ( Site 6612), Osaka

101-0041

Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6603), Tokyo

146-0095

Okawa Children & Family Clinic ( Site 6610), Tokyo

160-0022

Shinjuku Higashiguchi Clinic ( Site 6602), Tokyo

167-0051

Hayashi Clinic ( Site 6615), Tokyo

Ogikuboekimae Clinic ( Site 6601), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY